Navigation Links
Octapharma USA Submits BLA for octaplasLG®, a Therapy Targeting Adverse Transfusion Events
Date:2/27/2012

HOBOKEN, N.J., Feb. 27, 2012  /PRNewswire/ -- Octapharma USA has submitted its Biological License Application (BLA) for octaplasLG® to the U.S. Food and Drug Administration (FDA) with the goal of expanding its U.S. product portfolio by the fourth quarter of 2012.

The FDA will evaluate the octaplasLG® BLA for an indication of managing preoperative or bleeding patients who require replacement of multiple plasma coagulation factors. The application also seeks to gain marketing approval for the substitution of intentionally removed plasma, such as plasma exchange in patients with thrombotic thrombocytopenic purpura (TTP), a blood disorder that causes clot formation in small blood vessels. The product features solvent/detergent inactivation against enveloped viruses and immune neutralization against non-enveloped viruses.

"We look forward to bringing octaplasLG® to the U.S. medical community," said Octapharma USA President Flemming Nielsen. "This trusted therapy has been successfully used to treat patients for more than 15 years in Europe and over 30 countries worldwide."

Octapharma USA has started to lay the groundwork for the introduction of

SOURCE Octapharma USA
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Octapharma USA Appoints Global Biopharmaceutical Executive David E. Holliday as Vice President of Commercial Development
2. Octapharma Announces octagam® 5% Again Available for U.S. Purchase
3. FDA Approves U.S. Market Return for octagam® Following Octapharmas Implementation of Enhanced Safety Measures
4. Octapharma USA to Participate in Important Medical Meetings at AABB, NHF, ASHP and ASH
5. Octapharma Launches Clinical Trial to Evaluate Efficacy & Safety of wilate® In Preventing Surgical Bleeding in Type 3 von Willebrand Disease Patients
6. Octapharma USA Sponsors International Advisory Board for Evaluating Treatment of Patients with von Willebrand Disease
7. Octapharma Targets Primary Immune Deficiency Research With Grant for The Mount Sinai Medical Center
8. Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
9. Octapharma Accepting Applications for Research Grants Focused on Human Protein Therapies
10. Octapharma USA Launches Web Resource for von Willebrand Disease Healthcare Professionals and Patients
11. FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USAs New Therapy for Common Inherited Bleeding Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the world,s ... dental, animal health and medical practitioners, announced today that the ... , September 4, 2014 – Baird 2014 Healthcare Conference ... ET , September 8, 2014 – Morgan ... , NY at 1:25 p.m. ET Henry Schein,s ...
(Date:8/21/2014)... PARK, N.J. , Aug. 21, 2014 /PRNewswire/ ... pharmacy group purchasing organization (GPO), is pleased to ... to collaborate on a host of innovative specialty ... help Aurora deliver enhanced therapy management services to ... Management (OTM) system. Aurora will use ...
(Date:8/21/2014)... WOONSOCKET, R.I. , Aug. 21, 2014 CVS ... early tender results, applicable Reference Yields and consideration payable in ... Offers") commenced on August 7, 2014 for (1) any and ... and All Notes") and (2) up to a maximum amount ... due 2041 and 5.750% Senior Notes due 2017 (collectively, the ...
Breaking Medicine Technology:Henry Schein To Present At Two Investor Conferences In September 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6
... Ill., Nov. 8, 2010 ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... 8, 2010 Reportlinker.com announces that a ... its catalogue: The Future ... leading companies, and opportunities for target expansion ... G-Protein-coupled receptors (GPCRs) constitute the largest ...
Cached Medicine Technology:Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 2Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 3Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 4Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 5Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 6Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 7Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 8The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 2The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 3The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 4The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 5
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... American Corporate Health, was recently recognized as ... professionals in the field of workers’ compensation. ... Workers’ Compensation and Occupational Medicine Conference was ... attorneys, physicians, nurses, case managers, disability specialists, ...
(Date:8/21/2014)... As part of a continuing mission to ... joined with the Alliance for Safe Online Pharmacies (ASOP) ... sale of medicines. , “Helping to ensure the quality, ... a core mission for USP and an important tool ... T. Piervincenzi, chief executive officer of USP. “The illegal ...
(Date:8/21/2014)... 21, 2014 According to a new ... Optics Market-Global Industry Analysis, Size, Share, Growth, Trends and ... market was valued at USD 863.1 million in 2013 ... 7.6% from 2013 to 2019, to reach an estimated ... medical fiber optics market is witnessing significant growth due ...
(Date:8/21/2014)... According to a new market report ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast, ... valued at USD 236.1 million in 2011 and is ... in 2018 at a CAGR of 6.3% from 2012 ... Report: http://www.transparencymarketresearch.com/fundus-cameras.html . , Fundus cameras market growth ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 The worlds ... offer customers an exciting chance to grab free products. ... all-natural deodorant from Tom's of Maine with all qualifying ... deodorant and our environmentally friendly yoga apparel is simply ... The joint promotion between the two brands is intended ...
Breaking Medicine News(10 mins):Health News:Dr. Vasili Gatsinaris Named One of the Top 50 Most Influential in Workers’ Compensation 2Health News:USP Joins Efforts to Halt Illegal Online Drug Sales 2Health News:Global Medical Fiber Optics Market: Industry Analysis, Size, Share, Growth, Trend and Forecast 2013 - 2019 2Health News:Global Medical Fiber Optics Market: Industry Analysis, Size, Share, Growth, Trend and Forecast 2013 - 2019 3Health News:Global Medical Fiber Optics Market: Industry Analysis, Size, Share, Growth, Trend and Forecast 2013 - 2019 4Health News:Fundus Cameras Market: Product Type- Mydriatic, Non-Mydriatic, Hybrid and ROP Cameras; End Users- Hospitals, Ophthalmology Clinics and Ophthalmic & Optometrist Offices 2Health News:Tom's of Maine Partner up with BaliniSports Yoga Apparel 2
... and Company) (NYSE: BDX ), a global medical ... Bear Stearns 20th Annual,Healthcare Conference on Monday, September 10, ... of BD,s presentation can be accessed from the BD,corporate ... for replay,through Monday, September 17, 2007. BD, a ...
... Pa., Aug. 30 As part of his work,to ... health,insurance, Governor Edward G. Rendell today said 35,000 uninsured,individuals ... Insurance,Program will be given the opportunity to receive health ... insurance brings a sense of security and peace of ...
... pathway in the most common and aggressive type of ... to fuel tumor growth and help cancers evade drug ... In a series of laboratory and animal experiments, Johns ... with an experimental compound called cyclopamine to explore the ...
... reduce or prevent allergic reactions, group suggests , THURSDAY, ... people with seasonal allergies may suffer oral allergy syndrome ... pollen proteins from weeds, grass and trees and similar ... symptoms of OAS -- also known as pollen-food syndrome ...
... The sort of swelling that occurs when a joint ... the healing process, but when it comes to the knee, ... findings in experiments with pigs may lead to treatments for ... Medical Center orthopedic researchers. There are drugs that can block ...
... with the respiratory condition , , WEDNESDAY, Aug. 29 (HealthDay ... guidelines Wednesday that seek to make breathing easier and ... the lung disease. , "Asthma control is achievable for ... the National Heart, Lung, and Blood Institute, said during ...
Cached Medicine News:Health News:Governor Rendell Offers adultBasic Coverage to 35,000 Uninsured Pennsylvanians 2Health News:Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells 2Health News:Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells 3Health News:Pollen, Fruits, Veggies Help Trigger Oral Allergy Syndrome 2Health News:New insights into common knee injuries 2Health News:New Asthma Guidelines Stress Disease Control 2Health News:New Asthma Guidelines Stress Disease Control 3
Demineralized bone matrix dispensed in a jar. Fibers will be free of foreign matter. Glycerol 70-88% by weight. Calcium content less than 8%....
... Inductive demineralized bone matrix ... and cancellous chips will be ... bone matrix particle size is ... chip particle size is 1 ...
Demineralized cortical fibers and cancellous chips....
... positioning flexibility while permitting the components to be ... transport. The system has a small footprint to ... the same time offers the surgeon total control ... and display of the Stealthstation Treon can be ...
Medicine Products: